Technical Analysis for ZEAL - Zealand Pharma A/S

Grade Last Price % Change Price Change
grade C 32.61 -10.63% -3.88
ZEAL closed down 10.63 percent on Tuesday, November 19, 2019, on 1.71 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Flat
See historical ZEAL trend table...

Date Alert Name Type % Chg
Slingshot Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
MACD Bullish Signal Line Cross Bullish -10.63%
New 52 Week Closing High Bullish -10.63%
180 Bullish Setup Bullish Swing Setup -10.63%
Pocket Pivot Bullish Swing Setup -10.63%
New 52 Week High Strength -10.63%
Wide Bands Range Expansion -10.63%

Older signals for ZEAL ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Zealand Pharma A/S, a biotech company, engages in the discovery, design, and development of novel peptide-based medicines in Denmark. The company markets Lixisenatide, a once-daily prandial GLP-1 peptide receptor agonist for the treatment of type 2 diabetes under the Adlyxin and Lyxumia names; and Soliqua 100/33/Suliqua, a combination of lixisenatide and insulin glargine, and a GLP-1 receptor agonist for the treatment of type 2 diabetes. Its products under development include Glepaglutide, a novel GLP-2 analogue in Phase II clinical trials for the treatment of short bowel syndrome; Dasiglucagon, a ready-to-use hypo-pen in Phase II clinical trials to treat acute, severe hypoglycemia, as well as in Phase IIa clinical trials for pump-based diabetes management; Elsiglutide, a novel GLP-2 analogue in Phase II clinical trials to treat chemotherapy-induced diarrhea; and GLP1-GLU, a preclinical stage product for obesity/type 2 diabetes. The company has license agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Helsinn Healthcare S.A.; and Protagonist Therapeutics, Inc. Zealand Pharma A/S was founded in 1997 and is based in Copenhagen, Denmark.
Medicine Diabetes Chemotherapy Obesity Endocrine System Peptide Hormones Peptides Endocrinology Glucagon Like Peptide 1 Anti Diabetic Drugs Boehringer Ingelheim Severe Hypoglycemia
Is ZEAL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 36.84
52 Week Low 11.51
Average Volume 9,219
200-Day Moving Average 21.4924
50-Day Moving Average 27.3951
20-Day Moving Average 30.9022
10-Day Moving Average 32.71
Average True Range 1.8084
ADX 37.52
+DI 35.4916
-DI 25.6765
Chandelier Exit (Long, 3 ATRs ) 31.4148
Chandelier Exit (Short, 3 ATRs ) 31.8752
Upper Bollinger Band 35.8417
Lower Bollinger Band 25.9627
Percent B (%b) 0.67
BandWidth 31.968598
MACD Line 1.926
MACD Signal Line 1.8569
MACD Histogram 0.0691
Fundamentals Value
Market Cap 1 Billion
Num Shares 30.7 Million
EPS -0.63
Price-to-Earnings (P/E) Ratio -51.76
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 33.62
Resistance 3 (R3) 33.69 33.44 33.45
Resistance 2 (R2) 33.44 33.18 33.40 33.39
Resistance 1 (R1) 33.02 33.02 32.90 32.95 33.34
Pivot Point 32.77 32.77 32.70 32.73 32.77
Support 1 (S1) 32.35 32.51 32.23 32.28 31.88
Support 2 (S2) 32.10 32.35 32.06 31.83
Support 3 (S3) 31.68 32.10 31.77
Support 4 (S4) 31.61